ENTITY
Kindstar Globalgene Technology

Kindstar Globalgene Technology (9960 HK)

11
Analysis
Health CareHong Kong
Kindstar Globalgene Technology, Inc. operates as a clinical special inspection service provider. The Company provides blood biochemical monitoring, urine monitoring, and other services. Kindstar Globalgene Technology offers services in China.
more
Refresh
18 Apr 2023 00:46

ADICON Holdings IPO: The Bull Case

The key elements of the bull case rest on the growing non-COVID-19 testing addressable market, improving market sentiment, strong non-COVID-19...

Logo
275 Views
Share
15 Jul 2021 12:13

Kindstar (康圣环球) IPO Trading: Pattern of Demand Divergence

We look at the updates on Kindstar IPO since our last note. With its valuation higher than leading ICL peer, we do not expect a strong debut...

Logo
259 Views
Share
04 Jul 2021 10:21

ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
30 Jun 2021 03:19

Kindstar Globalgene IPO: Valuation Insights

At the mid-point of the IPO price range, the total net proceeds are HK$1,931.1 million ($250 million). Overall, we would participate in the IPO due...

Logo
387 Views
Share
29 Jun 2021 13:01

Kindstar Globalgene (康圣环球) IPO: Fairly Valued for a Questionable Moat

We think Kindstar is fairly valued for its fundamentals. Its moat is not as wide as many investors would think. Therefore we would avoid the deal.

Logo
323 Views
Share
x